Bellerophon Therapeutics Announces Last Patient Has Completed Blinded Treatment in Phase 3 REBUILD Study for INOpulse(R) in Fibrotic Interstitial Lung Disease

Source :: GlobeNewswire. May 11, 2023
Publication Year :: 2023
Abstract: WARREN, N.J., May 11, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) ('Bellerophon' or the 'Company'), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced [...]

Subjects :: Lung diseases -- Care and treatment
Nitric oxide -- Product development
Clinical trials
Banking, finance and accounting industries
Business

Tools